Investors

Global Links


Management Team

Investors

Press Releases

DateSubject
December 10, 2001 Cerus and Baxter Report Results in Trial of INTERCEPT Red Blood Cell System
December 10, 2001 Cerus and Baxter Present Phase III Results for the INTERCEPT Platelet and Plasma Systems At the American Society of Hematology Meeting
December 10, 2001 Cerus and Baxter Report Results in Trial of INTERCEPT Red Blood Cell System; Companies Reach Agreement with FDA on Pivotal Phase III Protocol
November 15, 2001 Cerus Corporation Names Bruce Cozadd to Board of Directors
October 23, 2001 Cerus Corporation Announces Third Quarter Results
October 17, 2001 Cerus and Baxter Report Positive Results in Trial of INTERCEPT Red Blood Cells
October 15, 2001 Cerus and Baxter Report Inactivation of Trypanosoma Cruzi Parasite; Data Demonstrates That Helinx Technology Inactivates Deadly Parasite Known to Cause Chagas Disease
October 4, 2001 Cerus Corporation Appoints David N. Cook as Vice President, Biotherapeutic Research and Development
August 17, 2001 Cerus and Baxter Report Primary Endpoint Met in U.S. Phase III Trial of the INTERCEPT Plasma System
August 17, 2001 Cerus and Baxter Report Primary Endpoint Met in U.S. Phase III Trial of the INTERCEPT Plasma System; Data Support Submission for U.S. Regulatory Approval
August 10, 2001 Cerus Corporation Files Shelf Registration Statement
July 26, 2001 Cerus Corporation Announces the Death of Dale A. Smith
July 24, 2001 Cerus Corporation Announces Second Quarter Results
July 21, 2001 Cerus Corporation Invites You to Join a Webcast of its Second Quarter Conference Call
July 16, 2001 Cerus and Baxter Report Additional INTERCEPT Platelet Data From European Phase III Trial
June 12, 2001 Cerus Receives Discover Magazine Innovation Award
May 17, 2001 Cerus Announces Private Placements Totaling $78 Million
April 24, 2001 Cerus Corporation Announces First Quarter Results
March 7, 2001 Cerus Corporation Receives $3.5 Million Award to Improve Safety of Blood Supply for U.S. Armed Forces
February 20, 2001 Cerus Corportation Names Vice President of Marketing
January 25, 2001 Cerus and Baxter Complete Enrollment in U.S. Phase III Trial of Intercept Platelet System
January 25, 2001 Cerus Corporation Announces Fourth Quarter and Year-end Results
January 23, 2001 Cerus Corporation Receives Broad U.S. Patent Covering Pathogen Inactivation in Blood
January 2, 2001 Cerus and Baxter Submit CE Mark Application for European Approval of the Intercept Platelet System